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Abstract
We introduce a methodology to efficiently exploit natural-language expressed biomedical knowledge for repurposing
existing drugs towards diseases for which they were not initially intended. Leveraging on developments in Computational
Linguistics and Graph Theory, a methodology is defined to build a graph representation of knowledge, which is
automatically analysed to discover hidden relations between any drug and any disease: these relations are specific paths
among the biomedical entities of the graph, representing possible Modes of Action for any given pharmacological
compound. We propose a measure for the likeliness of these paths based on a stochastic process on the graph. This
measure depends on the abundance of indirect paths between a peptide and a disease, rather than solely on the strength
of the shortest path connecting them. We provide real-world examples, showing how the method successfully retrieves
known pathophysiological Mode of Action and finds new ones by meaningfully selecting and aggregating contributions
from known bio-molecular interactions. Applications of this methodology are presented, and prove the efficacy of the
method for selecting drugs as treatment options for rare diseases.
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Introduction
In pharmaceutical research the subject of drug repurposing is
rapidly raising significant interest. Repurposing means redirection
of clinically advanced or marketed products into certain diseases
rather than in the initially intended indications. A significant
advantage of repurposing drugs is their demonstrated clinical
pharmacological efficacy and safety profile. Repurposing is
especially interesting in the area of life-threatening Rare or
Orphan diseases with high unmet medical need. The hypothesis
for drug repurposing is based on the drugs’ side effects profiles,
indicating interaction with more than one cellular target. These
pathway interactions open up the opportunity to exploit existing
medicines towards other diseases.
Extensive data sets describing drug effects have been published
globally, resulting in a huge amount of information publically
available in large on-line collections of bio-medical publications
such as PubMed (http://www.ncbi.nlm.nih.gov/pubmed/).
This is an opportunity for literature-based scientific discovery;
see [1–15,54], [2] and [3]. However, important pieces of
information regarding chemical substances, biological processes
and pathway interactions are scattered between publications from
different communities of scientists, who are not always mutually
aware of their findings. In order to generate a working hypothesis
from such a body of literature, a researcher would need to read
thoroughly all the relevant publications and to pick among them
the relevant items of information. Search engines help scientists in
this endeavour, but are unable to semantically aggregate
information from different sources, leaving all the initiative to
researchers; complex relation-focused and graph-like representa-
tions (ontologies) have been extensively produced and used to fill the
gap, since their introduction for the Semantic Web; see [16] and
[17]. Yet ontologies need to be man-made and they are difficult to
integrate each other and to maintain; see [18].
Here we propose an approach to literature-based research
ultimately based on the distributional hypothesis of linguistic theory (see
[19] and [20]) - whose analysis relates the statistical properties of
words association to the intrinsic meaning of a concept - and
network theory (see [21,22,54]) - a collection of versatile mathemat-
ical tools for representing interrelated concepts and analyse their
connections structure.
Main aim of this work is to provide a methodology for creating
network knowledge representations, capturing the essential entities
occurring in a variety of publications and connecting them into a
graph whenever they co-occur in a given sentence. The knowledge
graph thus created can then be analysed in order to identify and
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rank statistically relevant indirect connections among prospect
medicines and diseases. We show that with a suitable set of
concepts, specifically compiled in a dictionary, the linked
biochemical entities in the network can be connected along paths
that mimic a chain of reasoning and lead to prospect inferences
about the mechanism of action of a chemical substance in the
pathophysiology of a disease.
In this paper we introduce a method to rank the relevance of the
inferences, introducing a measure based on a stochastic process
(random walk) defined on the graph: this measure takes into
account all paths connecting two concepts and uses the abundance
and redundancy of these paths, together with their weights, as a
measure of the strength of the overall relation between the
concepts.
The paper is organized as follows: we first discuss the
construction of the knowledge graph; we then introduce the tools
to analyse this graph and extract possible mechanisms of action;
relevant emerging indirect links between peptides and sarcoidosis
are then discussed in the ‘Results’ section. A clinical reader might
skip the methodological part and go directly to the ‘Results’
section.
Methods
Construction of the knowledge graph
In the field of linguistics it is commonly accepted that the
meaning of a word must be inferred by examining its occurrences
over large corpora of text. Adopting this perspective (see [23–25]),
one can say that the meaning of a word ultimately depends on the
words it mostly goes along with: this is the basis of the so-called
‘‘Distributional Hypothesis’’ introduced by Firth in 1957. The
general idea shows that there is a correlation between distribu-
tional similarity and meaning similarity, which allows exploiting
the former in order to derive the latter. This hypothesis suggests
the assumption that concepts occurring in the same unit of text are
in some way semantically related. Let us note that co-occurrence is
nowadays a common method to find a relationship between
biomedical concepts; co-occurrence methods are commonly used
to discover new and hidden relations, following the seminal work
of Swanson (see [15], [25] and the more detailed works [26–30]).
Some authors (e.g. see [31–36]) use networks to map specific
biomedical entities such as protein-protein interactions, gene
regulatory events and links between proteins and phosphorylation
or genes interactions. Our aim is to build and use a co-occurrence
network of biomedical concepts to produce inferences that are new
hypotheses for drug repurposing. The key idea exploited in this
paper is that hopping through this knowledge network and
drawing a path between any two non-adjacent concepts can be
interpreted as suggesting a possible ‘‘sentence’’ that has never
actually been uttered but that can implicitly carry a new and
correct idea.
Let us here start by describing in details how our knowledge
network of peptides, related biological processes and rare diseases
is built (see Fig. 1). We have extracted three million PubMed paper
abstracts – out of a total of more than 20 million – using keyword
searches on a list of 1606 concepts, comprising 127 peptides, 300
rare diseases and 1179 other biological entities such as chemical
compounds, proteins, receptors, enzymes, hormones and physio-
logical entities (e.g. cells, organs, tissues, pathways, processes).
Every abstract has then been broken down into its constituent
sentences. The full list of concepts and the full list of paper IDs are
provided as File S1 and File S2. Entity recognition has been
carried out on every sentence, following a dictionary-based
approach (see [12,25]). Specifically, we built a dictionary,
enriching each item of our biomedical item list with a set of
acronyms, synonyms and other identifying phrases gathered from
MeSH (Medical Subject Headings), Orpha.net and the ‘‘cope with
cytokines’’ web site. Of course different concepts may share some
of the identifying expressions. This is the polysemy problem, i.e. the
capacity for a word or a phrase to have multiple meanings that
leads to the necessity of disambiguation (see [25], [37]). This is a
very complex problem in general and, to tackle with disambig-
uation, we employed a version of the Lesk algorithm (see [38]).
Whenever disambiguation fails, we have chosen to keep both the
possible concepts: this option reduces precision but maximizes
recall – i.e. the quantity of relevant concepts that are retrieved.
Many other errors in the detection of co-occurrences arise beyond
the ones due to failed disambiguation: a sentence boundary may
be misplaced, one of the occurrences may be a false positive or the
occurrences may be just part of a list (and therefore not
semantically related). It is expected though that as more and
more papers are analysed the meaningful co-occurrences will
outgrow the spurious ones: in fact ‘‘real’’ co-occurrences are
repeated consistently as more and more literature is considered,
while spurious ones become statistically insignificant because the
same concept is linked randomly to a great number of other
concepts. In a figurative manner we may think of a ‘‘noise’’ in the
co-occurrence detection that becomes negligible as a large number
of papers are considered. We thus obtain a co-occurrence network
(Fig. 2a) where the biomedical concepts of our dictionary are the
nodes and the co-occurrence frequency is the weight of the edges.
The resulting network is sparse with a small number of links
(158,428) compared to the complete graph (12.7%) but, nonethe-
less, only 30 concepts are not connected to the giant component of
the network, thus comprising 1576 nodes (98.13% of the total).
The diameter (i.e. the maximum distance between any two nodes)
of this network is 4 with an average path length (i.e. average
distance between any two nodes; see [9,10]) of 1.95. It is observed
that the graph contains hubs interpreted as physiological processes
typical of diseases (e.g. inflammation, proliferation, necrosis),
immune system-related items (e.g. white blood cells, cytokines) and
the major organs – especially the ones dealing with chemical
elaboration of drugs (e.g. kidney, liver). A number of direct
connections of ‘‘peptides – diseases’’ are present, such as ANGIO-
TENSIN – SARCOIDOSIS or ANGIOTENSIN – DIABETIC
NEPHROPATHY (see Fig. 2b). The relations between those
peptides and diseases are already known as we expected on the
ground that they appear together in a predicate. Indeed,
Angiotensin is known to worsen Sarcoidosis symptoms, while it
is of aid in diabetic nephropathy. These features are interpreted as
a positive feedback on the meaningfulness of the knowledge graph.
Analysis of the knowledge graph
Once the Knowledge Graph is built, we are in the position to
analyse it in order to highlight new scientifically analysable
relations between a peptide and a rare disease. We search for
indirect relations in the network (Fig. 2a) and therefore for a path
(see [21,22]) between a peptide and rare disease (Fig. 2b). Since all
nodes in the network are connected, these paths always exist: the
challenge is to rank them (in order to find the most significant
ones) and to explore and choose those paths that suggest
understandable and yet non-trivial inferences.
Shorter paths must be considered more relevant, as more steps
introduce new levels of indirection and magnify the effects of
randomness and noise. Yet the paths cannot be too short, because
they must be ‘‘verbose’’ enough to suggest a rationale to indicate
the biological Mechanisms of Action (MoA), i.e. a specific bioche-
mical interaction through which a drug substance produces its
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pharmacological effect amongst molecular targets like cell
receptors, proteins or enzymes; in other words the MoA explains
why and how a drug substance works. Specifically, when dealing
with peptides, the MoA, that we aim to replicate, is the one where
a peptide binds to its specific receptors, thus activating or
modulating a physiological process involved in the disease. To
achieve such characteristics, we consider specific interactions
(links) among nodes, filtering out unwanted information. For
instance, a peptide may be connected to any node but since we
look for mechanisms of actions, only links in the form of peptide–cell
receptor are allowed and therefore considered in the graph.
Similarly, a receptor can be either involved in a pathway or
influence directly a biological process, thus only links in the form
cell receptor–process or cell receptor–protein are allowed. To this purpose,
every item in our dictionary is assigned to one of the following
categories: AMINOACID, BACTERIA, CELL, DISEASE,
DRUG, ENZYME, GENE, HORMONE, NUCLEOTIDE,
ORGAN, OTHER, PATHWAY, PEPTIDE, PROCESS, PRO-
TEIN, RECEPTOR, VITAMIN.
From the mathematical perspective, co-occurrences define the
coefficients of the similarity matrix A representing the weighted
graph. Through a suitable normalization of A we are able to find a
probabilistic interpretation for the link weights. Specifically, posing
wij~
aijP
k aik
where aij is the i,j element of the similarity matrix, which is zero if
the vertices i,j are not directly connected and equal to the edge
weight otherwise (see also [54]). Therefore we interpret the
components wij as the conditional probability p(jDi) of finding
concept j in a co-occurrence containing concept i. Since the
coefficients of the matrix W are in the range (0,1], we can also
introduce a dissimilarity measure
d(i,j)~{ log (W )
which is correctly defined in the range d(i,j)[ 0,?½ Þ and,
Figure 1. Conceptual outline of the knowledge graph building process. (A) Every document is split into its constituent sentences and each
of them is scanned to identify expressions registered on the dictionary. In the figure, two sentences are highlighted and the matching expressions are
enclosed in coloured boxes. Every one of these expressions is associated to a concept in the dictionary. (B) The concepts co-occurring in a sentence
are connected pairwise. A sentence is therefore abstracted as a complete graph where the occurring concepts are the nodes and a single co-
occurrence is a link. The weight of a link is increased if more instances of the same co-occurrence are present. (C) The sentence graphs are then
merged in such a way that each node (concept) appears only once in the graph. In the figure it is evident that the «LAM» node (abbreviation for
Lymphangioleiomyomatosis – a rare disease) appears in every graph and the «Lung» node in two of them. (D) The result of the merging is a new
graph – which is no more complete – where the weight of the link is associated to the frequency of the same co-occurrence.
doi:10.1371/journal.pone.0084912.g001
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oppositely to weights returns larger values for smaller similarities.
This distance representation allows immediate application of the
available algorithms for computing shortest paths (see [22]). With
this definition, the shortest path between two any given nodes i
and j represents the most probable path (and therefore in our
interpretation, the most probable MoA) connecting them. In fact,
the shortest path is the one pij~iv1:::vkj that minimizes the total
distance
D(pij)~d(i,v1)zd(v1,v2)z:::zd(vk,j)
therefore, we have
D(pij)~{ logwiv1{:::{ logwvkj~{ log ( Pr,s[pij
wrs) ð1Þ
Since wij are conditional probabilities, the above equation (1) is a
product of conditional probabilities (a Markov chain). Therefore
the conditional probability associated to the shortest path is
maximized.
Ranking of paths using random walk
We have seen that shortest paths maximize the probability of a
single MoA, but strong indirect connections between a given
peptide and a given disease may arise also from a set of paths
which are smaller in weight but that contribute in larger numbers.
We have therefore devised a different ranking algorithm for a
peptide-disease correlation that considers all paths connecting the
two concepts and uses the abundance and redundancy of these
paths, together with their weights, as a measure of the strength of
the overall relation between the concepts.
This can be achieved by measuring the average number of time-
steps required to go from one vertex to the other in the network,
assuming that a walker is moving at random and that at each
discrete time-step it jumps from a vertex to one of its neighbours
with a probability which depends on the number of available links
and to their weights. This random walker produces a distance that is
a function of both the length and the abundance of paths
[55,56,57].
Intuitively, imagine two nodes connected by one short (one step)
path and many longer ones. A random walker trying the route
many times will tread the longer paths more often therefore
perceiving a ‘‘long’’ distance. Instead, if the end points are
connected with a lot of medium-sized paths, the walker will tread
those most of the times and thus perceiving a distance shorter than
the previous one. A common-world example for conveying this
idea: imagine a drunkard trying to go home. He is likely to make
many mistakes at the crossroads effectively selecting the next lane
at random. He is more likely to get home sooner if many roads
converge to his destination rather than if only a short one goes
there and the others lead astray.
From the computational perspective, the random walk distances
can be computed by pure algebraic means. The computation is
carried out defining a vector, where each component is the
likelihood that at a given time a random walker is on a given node.
The step-by-step evolution of this vector is a representation of the
shifting distribution of these walkers in the nodes in their random
wandering.
The probability to walk from vertex i to vertex j is defined in the
random walk theory by the transfer matrix P, computed from the
similarity matrix A with the formula:
pij~
aijP
k aik
~wij i,j~1,:::,N
which is exactly the matrix we have previously denoted W. It has
been shown (see [39]) that the random walk distances of two nodes
i and j are given by:
d(i,j)~
XN
k~1
1
I{B(j)
 
ik
where I is the identity matrix and B is a square matrix identical to
P having posed
B(j)ij~0 Vi
.The random walk distance built this way is non-symmetric, but for
Figure 2. Paths identification and selection. (A) This figure shows a version of the graph – simplified for illustration purposes – built focusing
onto 300 concepts and with 200,000 documents. (B) This figure shows three automatically retrieved and meaningful paths, identifying three – out of
five – prospect candidate peptides for sarcoidosis. The paths are depicted in a further simplified version of the graph obtained from the first one by
filtering out nodes not relevant to the paths.
doi:10.1371/journal.pone.0084912.g002
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our purposes we symmetrise it by taking the average of the two
directions.
ds(i,j)~
1
2
d(i,j)zd(j,i)½ 
This distance defines an implicit ranking measure for each couple
of distinct nodes and therefore between any peptide-disease
couple.
Such a measure can be interpreted as the probability of finding
that path, and thus the MoA, within the document base.
Results
In this paper we show examples of rationales produced by our
methodology with regard to a) the granulomatous disease
Sarcoidosis and its pulmonary pathology, and b) Imatinib, a
targeted-therapy agent against cancer cells, well known for its
apoptosis action.
Sarcoidosis is a disease in which abnormal collections of chronic
inflammatory cells form as nodules (granulomas) in multiple
organs. Sarcoidosis is present at various level of severity in all-
ethnic and racial groups and is mainly caused by environmental
agents in people with higher genetic sensitivity. The disease is a
chronic inflammatory disease that primarily affects the lungs but
can affect almost all organs of the body. Sarcoidosis is a complex
disease displaying incorrect functionalities within immune cells,
cytokines, and antigenic reactions; see [40]. Fig. 3 shows a
subgraph of the knowledge network comprising the concepts
related with Sarcoidosis.
We were interested in using peptides to treat Sarcoidosis.
Therefore a number of rationales have been obtained from a pool
of peptides against sarcoid pathologies, and the most relevant
findings are listed below, ranked according to the random walk
distance:
1. VIP – VIPR1 – INFLAMMATION – SARCOIDOSIS
2. a-MSH – HGFR – INFECTION – SARCOIDOSIS
3. CNP – NPRB – GUANYLIN_CYCLASE – INFLAMMA-
TION – SARCOIDOSIS
The Match VIP – SARCOIDOSIS
Vasoactive Intestinal Peptide - VIP (also known as Aviptadil), is
an endogenous human peptide. It is predominantly localized in the
lungs where it binds specific receptors (VPAC-1, VPAC-2), which
transform the signal into an increased production of intracellular
cyclic adenosine monophosphate (cyclic AMP or cAMP), as well as
into the inhibition of translocation of NF-kB from cytoplasm into
the nucleus. This process regulates the production of various
cytokines responsible for the inflammatory reaction, such as TNF-
a. Hence, VIP is responsible for preventing or attenuating a wide
variety of exaggerated pro-inflammatory activities; see [41].
The path in Fig. 4 shows that VIP is affecting the inflammation
processes related to Sarcoidosis.
The scientific evidence clearly suggests VIP as a potential
treatment option for Sarcoidosis: the system has been able to
retrieve the main receptor of VIP and its relevance in the
inflammation process.
Figure 3. The Sarcoidosis knowledge network. A portion of the knowledge network showing the neighbourhood of Sarcoidosis. The figure is
intended as a bird-eye view of the entities the system detected as related with Sarcoidosis
doi:10.1371/journal.pone.0084912.g003
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The Match ALPHA-MSH – SARCOIDOSIS
a-Melanocyte Stimulating Hormone (a-MSH) is an endogenous
peptide originally described for stimulating melanogenesis, mainly
for the pigmentation of the skin. Later it gained roles in feeding
behaviour, sexual activity, immune responses, inflammation and
fibrosis. Upon binding to its specific cell surface receptors it
increases production of cAMP in the target cells and triggers four
signalling pathways leading to the disruption of the transcription of
several pro-inflammatory mediators genes; see [41].
In addition, a-MSH also regulates the MET proto-oncogene
expression in both melanoma cells and in normal human
melanocytes. The MET proto-oncogene encodes for the Hepato-
cyte Growth Factor Receptor (HGFR) that is involved in
melanocyte growth and melanoma development; see [42].
There is evidence of interrelation between Epstein-Barr Virus
(EBV) infection and MET proto-oncogene expression, and at date
several infection agents have been suggested to have an
implication as cause of Sarcoidosis.
A role for a transmissible agent is also suggested by the finding
of granulomatous inflammation in patients without Sarcoidosis
who received heart transplantation from donors who had
Sarcoidosis; see [43] and [44].
The system sees both these processes (as apparent from Fig. 5),
assigning a better ranking to the second one. a-MSH is another
candidate for the treatment of the sarcoid-pathology due to this
double action.
The Match CNP – SARCOIDOSIS
CNP (C-type Natriuretic Peptide) is a human peptide, which
elicits a number of vascular, renal, and endocrine activities,
regulating blood pressure and extracellular fluid volume. When
CNP binds to its receptor, NPRB, on the cell surface it activates a
cell signalling through a Guanyl cyclase that increases intracellular
cGMP level activating specific pathways ultimately modifying
cellular functions. cGMP is known for its potent vasodilatory
action in pulmonary vessels. Depending on the tissues involved,
however, some of its effects are directly opposite to those of cAMP,
which is a potent inhibitor of proinflammatory tumor necrosis
factor (TNF-a) synthesis; see [45].
The inference subtended by the path in Fig. 6 is sound and
correctly traces a biological process. Yet CNP is not considered a
treatment option for Sarcoidosis because of its potential negative
side effects profile due to its systemic vasodilatory characteristics.
The Match Imatinib – Creutzfeldt-Jakob disease
Imatinib (commercialized under the name GLEEVEC) is a
rationally designed pyridylpyrimidine derivative, and a highly
potent and selective competitive tyrosine kinase inhibitor, espe-
cially effective in the inhibition of kinases c-Abl (Abelson proto-
oncogene), c-kit, and PDGF-R (platelet-derived growth factor
receptor); see [46] and [47]. These kinases are enzymes involved in
cellular signal transduction processes, whose dysregulation may
lead to malfunctioning of cells and disease processes, as
exemplified in a variety of hyperproliferative disorders and
cancers. Imatinib has been regulatory approved for chronic
myelogenous leukemia (CML), gastrointestinal stromal tumors
(GISTs), aggressive systemic mastocytosis (ASM), hypereosinophi-
lic syndrome (HES), chronic eosinophilic leukemia (CEL),
dermatofibrosarcoma protuberans, and Acute Lymphoblastic
Leukemia (ALL).
Exploiting our methodology we looked for rationales for the
redirection of Imatinib; on the basis of the results of the stochastic
measure, the system indicates the neurodegenerative transmissible
spongiform encephalopathies – exemplified by the Creutzfeldt-
Jakob disease (CJD) – as promising targets for this drug.
Transmissible spongiform encephalopathies are caused by the
aberrant metabolism of the prion protein (PrP). Prions are
seemingly infectious agents without a nucleic acid genome. Prion
diseases belong to the group of neurodegenerative diseases
Figure 4. The VIP – SARCOIDOSIS path and other closely related concepts.
doi:10.1371/journal.pone.0084912.g004
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acquired by exogenous infection and have a long incubation
period followed by a clinical course of progressive dementia,
myoclonal ataxia, delirious psychomotor excitement, and neuronal
death; see [48].
Moreover, the system selects the path (see Fig. 7) that indicates
the kinase c-Abl effect on cell-apoptosis as key MoA for redirecting
Imatinib towards CJD. In fact, the c-Abl tyrosine kinase is found to
be over-activated in neurodegenerative diseases like Alzheimer’s
disease and Parkinson’s diseases, and overexpression of active c-
Abl in adult mouse neurons results in neurodegeneration and
neuroinflammation; see [49]. There is clear experimental evidence
that activation of c-Abl leads to neuronal cell death and neuronal
Figure 5. The a-MSH – SARCOIDOSIS path and other closely related concepts.
doi:10.1371/journal.pone.0084912.g005
Figure 6. The CNP – SARCOIDOSIS path and other closely related concepts.
doi:10.1371/journal.pone.0084912.g006
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apoptosis in experimental Creutzfeldt-Jakob disease; see [50].
Imatinib has been shown to prevent c-Abl kinase induced
apoptosis in animal models of neurodegeneration; see [51].
Finally, Imatinib was shown to clear prion-infected cells in a time
and dose-dependent manner from misfolded infectious protein
without influencing the normal biological features of the healthy
PrP, and Imatinib activated the lysosomal degradation of pre-
existing misfolded PrP; see [52]. This provides a sound rationale
for the proposed redirection.
The system indicated also Imatinib as a treatment option for
pulmonary arterial hypertension (PAH), via its potent inhibitory
effect on the PDGF Receptor (PDGF-R). For the indication PAH,
the drug is however not approved.
Conclusions
A double-layer methodology is presented, consisting of semantic
analysis – leveraging on developments of Computational Linguis-
tics – and graph analysis – exploiting Graph Theory and
Stochastic Process Theory tools. This methodology has allowed
the screening of more than 3 million abstracts from PubMed-
published biomedical papers and the detection of relevant
concepts identified by dictionary-defined expressions; concepts
have been mapped as nodes of a graph, whose links are defined by
co-occurrence of concepts across roughly 30 million of sentences.
Specifically, the pathophysiological connections between peptides
and diseases have been detected in order to provide inferences for
biomedical rationales for drug repurposing.
The proposed methodology provides an effective instrument to
detect different MoAs of peptides and drugs; though it may not
capture the full-detail of the MoAs, it succeeds in making them
recognizable by a short chain of biomedical entities. Moreover, the
graph representations of biomedical knowledge seen above
produces a sound and meaningful representation of the many
interrelated concepts of the biomedical discipline; such method-
ology successfully allows both the validation of existing rationales
and the discovery of new ones, a feat usually left to serendipity and
intuition. We have translated the scientific rationales in relevant
clinical trial settings into new potential treatment options for the
affected patients in Sarcoidosis.
Our methodology confirmed the result of an open clinical phase
II study, where we treated 20 patients with histologically proven
Sarcoidosis and active disease with nebulized VIP for 4 weeks.
This study is the first to show that VIP has clear, positive, immune-
regulatory effects in sarcoid patients without any obvious side
effects and without systemic immuno-suppression. VIP should
therefore be developed as an attractive therapeutic option for
patients with pulmonary Sarcoidosis; see [53]. We have initiated a
clinical ex-vivo trial to prove a-MSH in a sarcoid pathology.
Preliminary data clearly suggest a beneficial outcome of the
experimentation (unpublished data), clearly suggesting a-MSH as
another potential treatment option for this pathology.
Moreover, the case for Imatinib as a treatment option for the
Creutzfeldt-Jakob disease shows how the system is able to produce
a sound scientific rationale also for non-peptide drugs and with a
mechanism of action quite different from the others, thus proving
a much wider applicability.
Results are more noteworthy if the relative slimness of the
dictionary is taken into account. Better representations are to be
expected defining more detailed and more comprehensive
dictionaries. Furthermore, Graph Theory tools provide quite an
interesting arsenal of instruments to analyse a complex network of
nodes (biological and medical concepts) and highlight hidden
inferences across biochemical compounds, clinical data and
medical concepts.
As it is apparent from this presentation the specific field of
application enters the methodology in the broad selection of the
document base and in the definition of the dictionary: the inner
mechanism of knowledge representation and analysis is quite
independent of it.
We would like to stress that here we have provided only very
general characterization of the knowledge network and focused
onto very well consolidated tools of analysis. But the field of
complex networks is currently under massive development,
Figure 7. Imatinib (GLEEVEC) – Creutzfeldt-Jakob Disease path and other closely related concepts.
doi:10.1371/journal.pone.0084912.g007
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providing ever more subtle indicators of graph features and related
techniques of analysis. We therefore think that our reliance on the
combination of the knowledge network inference with our random
walk rankings poses this method in the best position to exploit this
development and may well prove to make it mainstream in the
field of text mining.
This methodology can be applied to other fields: for sure it can
be extended over broader biomedical research, transcending
peptides to study other chemical compounds and also focusing on
diseases other than rare. We think it can be applied to any field of
research – even outside natural science – provided that a suitable
amount of literature is available and that the main issue be the
association of a great number of particular facts and observation
that do not yet fit into an already understood and comprehensive
scheme.
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